Anavex Life Sciences Corp (AVXL)

[sokol]

Inflammation. It’s good to see scientists coming around to targeting inflammation re: Alzheimer’s. Anavex has been speaking about inflammation and oxidative stress for quite sometime. See for example:

“Both data sets described that Aß1-42 (amyloid beta) significantly impairs biological function in the respective animal models and the observed regain of function confirmed the protective potential of ANAVEX sigma-1 receptor agonists against amyloid beta -induced toxicity. The former presentation further reported that although that the transgenic McGill rats had a very late stage of Alzheimer’s disease-like pathology (13 months of age), treatment with ANAVEX 3-71 fully reversed cognitive deficits, reduced amyloid pathology and also significantly reduced inflammation. Furthermore, the sustained recovery in cognition and pathophysiology observed following a month-long washout phase in advanced pathology (19 months of age) strongly suggests true disease-modifying properties of ANAVEX 3-71.”

See. Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor. http://www.anavex.com/anavex-life-sciences-reports-new-mechanism-action-data-related-anavex-compounds-targeting-sigma-1-receptor/

“McGill University’s Hélène Hall, PhD, delivered the first poster presentation, “Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP rats.” This study showed that, using transgenic mice with Alzheimer’s-like amyloid pathology, compound Anavex 3-71 (five months of daily treatment), reduced inflammatory response in the brain and increased synaptogenesis. Furthermore, the compound decreased amyloid pathology and fully reversed Alzheimer’s-related cognitive deficits.”

“Besides the well-known accumulation of amyloid beta peptide and the formation of senile plaques, researchers have extensively described the brain inflammation and reduced synaptogenesis (the formation of new synapses between neurons) in Alzheimer’s.”

See Compounds that Target Sigma-1 Receptor Offer Promise in Battling Alzheimer’s, Says Anavex. https://alzheimersnewstoday.com/2017/04/06/anavex-sigma-1-receptor-agonists-ad-therapy/